Pharmaceuticals

Imperial College London is a hive of activity in drug discovery and development. Imperial hosts some of the world’s leading scientists as well as the affiliation with Imperial NHS trust, one of the largest academic health systems in Europe.

Based on these cutting edge capabilities, ICON has a proven record in assisting pharmaceutical companies and CROs to develop successful, ground-breaking medicines.

Our consultants are key opinion leader physicians and globally renowned researchers, who are committed to translating their expertise into practice in order to push the boundaries of drug development.

We have helped clients solve a range of problems:

 

SCIENTIFIC AND REGULATORY ADVICE AND PROTOCOL ASSISTANCE

Our academics have offered scientific, regulatory advice as well as assistance with clinical trial protocols in all therapeutic classes including rare diseases.`

 

PRE-CLINICAL DEVELOPMENT

Validated disease models in multiple therapeutic areas, high throughput screening, assays, pre-clinical species PK/PD, imaging, medicinal chemistry, structural synthesis pathways and lead optimisation strategy.

 

VACCINE DEVELOPMENT

Identification of antigens, reverse vaccinology, vaccine challenge tests for RSV, malaria and influenza.

 

MOLECULAR DIAGNOSTICS UNIT (MDU)

The CPA-accredited Molecular Diagnostic Unit (MDU) provides fast, accurate diagnostic tests for the management of infectious and genetic diseases using latest technology, including next generation sequencing and UPLC. Through ongoing research and development of new diagnostic methods it strives to remain ahead of the field in diagnostic testing and clinical monitoring.

The MDU supports the HIV and HTLV trials of the Clinical Trials Centre and patient management for The National Centre for Human Retrovirology and Imperial College Healthcare Trust.

Work to date has been centred on HIV, hepatitis viruses and sexually transmitted infections – but the clinical requirements of other clients can be catered for, click for more details

 

 

ACCESS TO FACILITIES

Genomics, biomarker discovery, high throughput mass spec, NMR, X-ray crystallography, advanced PET, advanced MRI, functional MRI and quantitative image analysis using AI.

Whether you need help with pre/clinical development or access to cutting edge validated assays and disease models, we can find the right people to help you solve a problem flexibly and responsively.

Advisory services

Product design, research methods, data analysis, technology evaluation for investment, technological innovation, patent evaluation, prototype and protocol development, policy, cyber security and more. Assisting museums, writers, film makers and artists to ensure creations scientifically sound.

Expert insight

Membership of Scientific Advisory Boards and Technical Panels, advice and guidance on drug development programmes, thought leadership, conference speakers, literature reviews and provision of foresight.

Analysis and testing

Use of the world-class specialist facilities and technicians at Imperial for projects ranging from aerodynamic measurements and medical imaging to structural testing and analysis.

Our consultants are world-leading experts in their field, committed to on-going research.

Related Insights

Life after lockdown: Transport

Life after lockdown: Transport

COVID-19 has changed everything. Or has it? How can transport companies, commuters and consumers adjust? Planes, trains and automobiles - best practice, e-mobility and air quality discussed. read more

Factories of the Future

Factories of the Future

Additive manufacturing is an automated production process enabling complex 3D designs to be transformed into physical objects. Read about the benefits and implications. read more

Life after lockdown: COVID-19 response

Life after lockdown: COVID-19 response

Imperial's experts, from a wide range of disciplines, have and continue to keep us informed about COVID-19 and the coronavirus response, save lives through vaccines and testing - and provide solutions to protect the NHS. read more

Related case studies

Hepatitis C genotype and drug resistance testing

Hepatitis C genotype and drug resistance testing

Genotype and resistance testing for new direct-acting antiviral (DAA) drugs designed to treat Hepatitis C virus (HCV). read more

Imperial College London Diabetes Centre

Imperial College London Diabetes Centre

The Imperial College London Diabetes Centre was established in Abu Dhabi, in 2006, by Mubadala and experts from Imperial to address the demand for diabetes care in the UAE. With continued support from Imperial, the centre now operates three branches across Abu Dhabi and Al Ain and public health initiatives. read more

Design advice on eco-ventilation system for homes

Design advice on eco-ventilation system for homes

Our consultants shared their expertise in sustainable energy system design to help Clean Tech start up ‘Ventive Ltd’ to move into new markets with their PVHR (passive ventilation with heat recovery) system. read more

Latest news

Gravity-based energy storage could prove a cheaper option

Gravity-based energy storage could prove a cheaper option

Imperial researchers predict that gravity-fed energy storage systems may provide long-term savings - and analysis suggests that technology from Gravitricity is well suited to provide grid balancing and rapid frequency response services to grid operators. read more

Improving service through bus priority schemes

Improving service through bus priority schemes

Transport Strategy Centre (RTSC) study investigates the use of priority measures for bus services in 14 cities across Asia, Australia, Europe and North America and provides best practice for decision makers charged with improving service and efficiency. read more

Tackling London’s air pollution will increase life expectancy of children

Tackling London’s air pollution will increase life expectancy of children

Report by researchers from Environmental Research Group predicts London air quality policies, and wider improvements in air quality, will increase average life expectancy of a child born in London in 2013 by six months. read more